Advertisement
BIO vs ILMN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and ILMN is a Hold.
BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 63 cases where BIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIO as a result. In 70 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for BIO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 37 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
BIO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ILMN's Indicator enters downward trend
The Aroon Indicator for ILMN entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator formed such a pattern. In 181 of the 204 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ILMN as a result. In 76 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 37 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
ILMN moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ILMN crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ILMN's RSI Oscillator exited the oversold zone, 17 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 206 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ILMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.340) is normal, around the industry mean (67.298). P/E Ratio (39.542) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
BIO | ILMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 31 | |
PRICE GROWTH RATING 1..100 | 23 | 43 | |
P/E GROWTH RATING 1..100 | 2 | 10 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ILMN's Valuation (83) in the Biotechnology industry is in the same range as BIO (91) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BIO’s over the last 12 months.
ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIO (100) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BIO’s over the last 12 months.
ILMN's SMR Rating (31) in the Biotechnology industry is somewhat better than the same rating for BIO (87) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than BIO’s over the last 12 months.
BIO's Price Growth Rating (23) in the Medical Specialties industry is in the same range as ILMN (43) in the Biotechnology industry. This means that BIO’s stock grew similarly to ILMN’s over the last 12 months.
BIO's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as ILMN (10) in the Biotechnology industry. This means that BIO’s stock grew similarly to ILMN’s over the last 12 months.
| BIO | ILMN | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 83% |
| Advances ODDS (%) | 6 days ago 65% | 6 days ago 76% |
| Declines ODDS (%) | 2 days ago 69% | 2 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 79% |
| Aroon ODDS (%) | 4 days ago 68% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green while ILMN’s FA Score has 2 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- ILMN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 2 TA indicator(s) are bullish while ILMN’s TA Score has 4 bullish TA indicator(s).
- BIO’s TA Score: 2 bullish, 7 bearish.
- ILMN’s TA Score: 4 bullish, 6 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -3.99% price change this week, while ILMN (@Medical Specialties) price change was -2.87% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was -4.49%, and the average quarterly price growth was -5.80%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
Reported Earning Dates
BIO is expected to report earnings on Feb 18, 2027.
ILMN is expected to report earnings on Feb 11, 2027.
Industries' Descriptions
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.